We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-3.44%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.06B
AUM Growth
-$462M
Cap. Flow
-$399M
Cap. Flow %
-37.47%
Top 10 Hldgs %
54.06%
Holding
50
New
9
Increased
12
Reduced
4
Closed
13

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$58.9M
2
ESRX
Express Scripts Holding Company
ESRX
+$49.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$38.1M
4
OFIX icon
Orthofix Medical
OFIX
+$36.2M
5
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$26.3M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$75.3M
2
CYH icon
Community Health Systems
CYH
+$63M
3
HCA icon
HCA Healthcare
HCA
+$50.7M
4
THC icon
Tenet Healthcare
THC
+$42.2M
5
LH icon
Labcorp
LH
+$41M

Sector Composition

Rank Sector Weight
1 Healthcare 71.35%
2 Consumer Discretionary 2.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTIC
26
DELISTED
Otonomy, Inc.
OTIC
$13.8M 1.29%
+573,000
New +$11.3M
AMRN
27
Amarin Corp
AMRN
$298M
$13.1M 1.23%
600,000
+50,000
+9% +$1.63M
CCRN
28
DELISTED
Cross Country Healthcare
CCRN
$9.29M 0.87%
1,000,000
+202,158
+25% +$1.55M
CRDC
29
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$8.96M 0.84%
837,485
– –
GNMK
30
DELISTED
GenMark Diagnostics, Inc
GNMK
$8.15M 0.77%
908,100
– –
PTCT icon
31
PTC Therapeutics
PTCT
$6.26B
$6.96M 0.65%
+158,149
New +$4.95M
GERN icon
32
Geron
GERN
$860M
$6.88M 0.65%
3,440,045
-1,849,955
-35% -$4.56M
BIOL
33
DELISTED
Biolase, Inc.
BIOL
$6.76M 0.64%
217
– –
ANGO icon
34
AngioDynamics
ANGO
$610M
$5M 0.47%
364,630
-19,000
-5% -$271K
PLX icon
35
Protalix BioTherapeutics
PLX
$183M
$4.84M 0.45%
200,000
– –
GYRE icon
36
Gyre Therapeutics
GYRE
$648M
$3.95M 0.37%
1,981
– –
INO icon
37
Inovio Pharmaceuticals
INO
$54M
$2.46M 0.23%
+20,833
New +$2.6M
BLUE
38
DELISTED
bluebird bio
BLUE
– –
-50,713
Closed -$25.3M
CYH icon
39
Community Health Systems
CYH
$391M
– –
-1,679,359
Closed -$63M
ELV icon
40
Elevance Health
ELV
$81.6B
– –
-700,000
Closed -$75.3M
HAE icon
41
Haemonetics
HAE
$3.85B
– –
-1,000,000
Closed -$35.3M
HCA icon
42
HCA Healthcare
HCA
$85.7B
– –
-900,000
Closed -$50.7M
LH icon
43
Labcorp
LH
$25.9B
– –
-465,600
Closed -$41M
SPY icon
44
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
– –
-1,500,000
Closed -$294M
THC icon
45
Tenet Healthcare
THC
$20.3B
– –
-900,000
Closed -$42.2M
RVNC
46
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-630,000
Closed -$21.4M
HRC
47
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-893,223
Closed -$37.1M
TRNX
48
DELISTED
TORNIER N V SHARES (NLD)
TRNX
– –
-573,655
Closed -$13.4M
FURX
49
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
– –
-200,000
Closed -$21.2M
RPRX
50
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-390,370
Closed -$6.75M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Camber Capital Management held 50 positions worth $1.06B, down 30% from $1.53B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Camber Capital Management withdrew a net $399M in Q3 2014, closing 13 positions and reducing 4 holdings. Its most notable exit was Elevance Health, an estimated $75.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 62% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Camber Capital Management opened a new position in GSK worth $55.2M.

  • Camber Capital Management's largest Q3 2014 buy was GSK: 960,000 shares worth $55.2M.
  • Camber Capital Management added most to Orthofix Medical in Q3 2014, an estimated $36.2M increase.
  • Camber Capital Management's biggest Q3 2014 reduction was Quest Diagnostics, cutting an estimated $37M.
  • Camber Capital Management fully exited Elevance Health in Q3 2014, selling an estimated $75.3M.
  • Camber Capital Management's ten largest holdings make up 54% of its $1.06B portfolio in Q3 2014.
  • Camber Capital Management opened 9 new positions and closed 13 in Q3 2014.
  • Camber Capital Management's portfolio value fell 30% quarter-over-quarter to $1.06B.

Based on Camber Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.